TuisMOR • ETR
add
MorphoSys AG
Vorige sluiting
€67,65
Dagwisseling
€67,65 - €68,00
Jaarwisseling
€14,52 - €69,75
Markkapitalisasie
2,55 mjd EUR
Gemiddelde volume
66,52 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
ETR
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (EUR) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 27,54 m | 13,11% |
Bedryfskoste | 289,14 m | 264,02% |
Netto inkomste | -314,96 m | -608,87% |
Netto winsgrens | -1,14 k | -526,67% |
Wins per aandeel | -8,27 | -529,19% |
EBITDA | -263,38 m | -388,32% |
Effektiewe belastingkoers | 0,51% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (EUR) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 630,77 m | -20,30% |
Totale bates | 1,83 mjd | -17,85% |
Totale aanspreeklikheid | 2,09 mjd | -1,84% |
Totale ekwiteit | -261,67 m | — |
Uitstaande aandele | 37,62 m | — |
Prys om te bespreek | -9,72 | — |
Opbrengs op bates | -34,27% | — |
Opbrengs op kapitaal | -41,11% | — |
Kontantvloei
Netto kontantverandering
| (EUR) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -314,96 m | -608,87% |
Kontant van bedrywe | -71,53 m | 14,27% |
Kontant van beleggings | 28,62 m | 187,62% |
Kontant van finansiering | -950,28 k | 97,86% |
Netto kontantverandering | -27,24 m | 75,37% |
Beskikbare kontantvloei | 246,91 m | 1 523,66% |
Meer oor
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Gestig
1992
Hoofkwartier
Webwerf
Werknemers
464
